<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="192807">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00582283</url>
  </required_header>
  <id_info>
    <org_study_id>CO02505</org_study_id>
    <secondary_id>R21CA092412</secondary_id>
    <secondary_id>124I-CLR1404</secondary_id>
    <nct_id>NCT00582283</nct_id>
  </id_info>
  <brief_title>NM404 as an Imaging Agent in Patients With NSCLC</brief_title>
  <official_title>NM404 as an Imaging Agent in Patients With Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cellectar Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine imaging characteristics of radiolabelled 131-I-NM404 in ten
      patients with cancer, including calculations of PKs, radiation dosimetry, biodistribution,
      and optimal imaging times (part 1 - complete).

      In addition, specific tumor accumulation and metabolic fate of 131-I-NM404 will be
      determined in NSCLC tumors collected in 5 patients (part 2 - complete). Lastly, the study
      will collect preliminary data on imaging NSCLC tumors in up to 12 patients with evaluable
      disease (part 3 - ongoing).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Imaging characteristics</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor accumulation and metabolic fate of NM404 in tissue</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Data</measure>
    <time_frame>1, 2, 3 and 5-7 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic: iodine I-124 NM404 CT/PET scan</arm_group_label>
    <description>Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I124-NM404</intervention_name>
    <description>I-124-NM404</description>
    <arm_group_label>Diagnostic: iodine I-124 NM404 CT/PET scan</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-small cell lung cancer treated at University of Wisconsin Hospital and
        Clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Part 3

          -  Histologically or cytologically documented NSCLC with measurable of disease

          -  Disease is evaluable by CT scan

          -  At least 18 years old. Women cannot be pregnant or breastfeeding

          -  Karnofsky score &gt;/= to 60

          -  Adequate renal/hepatic function

          -  Adequate blood cell count levels

        Exclusion Criteria:

          -  Concomitant infection

          -  Other active cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne M Traynor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 25, 2017</lastchanged_date>
  <firstreceived_date>December 19, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
